Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).
Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, Douillard JY, Thatcher N, Barlesi F, Owonikoko T, Wang Y, Pultar P, Zhu J, Malik R, Giaccone G; FORTIS-M Study Investigators. Ramalingam S, et al. Ann Oncol. 2013 Nov;24(11):2875-80. doi: 10.1093/annonc/mdt371. Epub 2013 Sep 19. Ann Oncol. 2013. PMID: 24050956 Free article. Clinical Trial.
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. Horn L, et al. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280641 Clinical Trial.
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Soria JC, et al. Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5. Lancet Oncol. 2015. PMID: 26156651 Clinical Trial.
Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome.
Derosa L, Iebba V, Silva CAC, Piccinno G, Wu G, Lordello L, Routy B, Zhao N, Thelemaque C, Birebent R, Marmorino F, Fidelle M, Messaoudene M, Thomas AM, Zalcman G, Friard S, Mazieres J, Audigier-Valette C, Sibilot DM, Goldwasser F, Scherpereel A, Pegliasco H, Ghiringhelli F, Bouchard N, Sow C, Darik I, Zoppi S, Ly P, Reni A, Daillère R, Deutsch E, Lee KA, Bolte LA, Björk JR, Weersma RK, Barlesi F, Padilha L, Finzel A, Isaksen ML, Escudier B, Albiges L, Planchard D, André F, Cremolini C, Martinez S, Besse B, Zhao L, Segata N, Wojcik J, Kroemer G, Zitvogel L. Derosa L, et al. Among authors: scherpereel a. Cell. 2024 Jun 20;187(13):3373-3389.e16. doi: 10.1016/j.cell.2024.05.029. Cell. 2024. PMID: 38906102 Free article.
The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity.
Willems M, Hamaidia M, Fontaine A, Grégoire M, Halkin L, Vilanova Mañá L, Terres R, Jamakhani M, Deshayes S, Brostaux Y, Heinen V, Louis R, Duysinx B, Jean D, Wasielewski E, Scherpereel A, Blanquart C, Willems L. Willems M, et al. Among authors: scherpereel a. EBioMedicine. 2024 Nov;109:105418. doi: 10.1016/j.ebiom.2024.105418. Epub 2024 Oct 30. EBioMedicine. 2024. PMID: 39471751 Free PMC article.
Long Covid: a global health issue - a prospective, cohort study set in four continents.
Pazukhina E, Garcia-Gallo E, Reyes LF, Kildal AB, Jassat W, Dryden M, Holter JC, Chatterjee A, Gomez K, Søraas A, Puntoni M, Latronico N, Bozza FA, Edelstein M, Gonçalves BP, Kartsonaki C, Kruglova O, Gaião S, Chow YP, Doshi Y, Duque Vallejo SI, Ibáñez-Prada ED, Fuentes YV, Hastie C, O'Hara ME, Balan V, Menkir T, Merson L, Kelly S, Citarella BW, Semple MG, Scott JT, Munblit D, Sigfrid L; ISARIC Clinical Characterisation Group and ISARIC Global Covid-19 follow up working group. Pazukhina E, et al. BMJ Glob Health. 2024 Oct 21;9(10):e015245. doi: 10.1136/bmjgh-2024-015245. BMJ Glob Health. 2024. PMID: 39433402 Free PMC article.
Survival and Prognostic Factors After Adrenalectomy for Secondary Malignancy: A Combined Analysis of a French University Center Registry (Eurocrine) of 307 Patients and a French Nationwide Study of 2515 Patients.
Rémond A, Marciniak C, Lenne X, Chouraki V, Gobert M, Baud G, Maillard L, Bouriez D, Liekens E, Donatini G, Nominé-Criqui C, Ravenet A, Santucci N, Kuczma P, Bouviez N, Tresallet C, Mirallié E, Deguelte S, Brunaud L, Guerin C, Gronnier C, Lifante JC, Bruandet A, Theis D, Cortot A, Scherpereel A, Hamroun A, Pattou F, Caiazzo R. Rémond A, et al. Among authors: scherpereel a. Ann Surg. 2024 Nov 1;280(5):825-834. doi: 10.1097/SLA.0000000000006479. Epub 2024 Aug 7. Ann Surg. 2024. PMID: 39109429
222 results